Cognitive functioning and health-related quality of life in long-term anaplastic oligondendroglioma and oligoastrocytoma survivors from the EORTC 26951 study: second follow-up - Follow-up of anaplastic oligondendroglioma and oligoastrocytoma patients

Haaglanden Medisch Centrum0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients are eligible for participation if they meet the following criteria:
•1) They are diagnosed with an anaplastic oligodendroglioma or oligoastrocytoma;
•2) They are adults; over 18 years old;
•3) They participated in EORTC 26951 study and the first follow-up study;
•4) They have signed the informed consent form, or, when unable to decide, their
•legal representative signed the informed consent form for their participation
•and the use of their data., Proxies are eligible for participation if they meet
•the following criteria:
•1) The patient is not deemed able to participate (as judged by the treating
•physician) due to a poor physical or mental condition;
•2) The patient has given consent that the proxy may participate on his behalf;
•3) In the situation that the patient is deemed unable to decide, the legal
•representative of the patient has signed the informed consent form to
•participate;
•4) The proxy has signed the informed consent form stating he/she agrees to
•participate;
•5) They are adults; over 18 years old.

•Patients are not considered eligible for study participation if:
•1) They are not eligible for participating in the study according to the
•treating physician, due to severe physical or mental impairments hampering
•filling in the questionnaires or undergoing the cognitive tests;
•2) They are unable to communicate adequately., Proxies are not considered
•eligible for study participation if:
•1) They are unable to communicate adequately;
•2) The patient, or his/her legal representative, has not signed the informed
•consent form for proxy participation;
•3) They proxy him- or herself has not signed his/her own informed consent form.

发起方